News
An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.
The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.
Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...
Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...
Viatris (VTRS) stock dips after its experimental therapy for eyelid inflammation fails a Phase 3 trial. Read more here.
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...
This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results